Non-Responsive Diabetic Macular Edema and Spironolactone
Status:
Not yet recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
Diabetic patients with macular edema and choroidal hyperpermeability (as manifested as a
thick choroid on OCT (optical coherence tomography) and ICG hyperfluorescence on ICG)
unresponsive to anti-VEGF (vascular endothelial growth factor) and steroid injections will be
treated with spironolactone in addition to the continued treatment of anti-VEGF injections,
specifically aflibercept (Eylea).